| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1,191,900 | 1,259,600 | 1,209,300 | 1,157,100 |
| Cost of sales | 441,600 | 466,900 | 477,900 | 468,300 |
| Gross profit | 750,300 | 792,700 | 731,400 | 688,800 |
| Research and development | 145,300 | 148,200 | 157,500 | 148,200 |
| Selling, general and administrative | 349,700 | 321,500 | 331,400 | 328,000 |
| Total operating expenses | 495,000 | 469,700 | 488,900 | 476,200 |
| Operating income | 255,300 | 323,000 | 242,500 | 212,600 |
| Other income, net | 14,200 | 17,700 | 109,800 | 28,500 |
| Income before income taxes | 269,500 | 340,700 | 352,300 | 241,100 |
| U.s. federal statutory rate | NaN | 67,525* | NaN | NaN |
| State and local income tax, net of federal income tax effect | NaN | 4,100* | NaN | NaN |
| Foreign rate differential-IE | NaN | 15,900* | NaN | NaN |
| Changes in valuation allowance-IE | NaN | -18,625* | NaN | NaN |
| Other-IE | NaN | 1,450* | NaN | NaN |
| Foreign rate differential-MY | NaN | -3,700* | NaN | NaN |
| Other-MY | NaN | 2,225* | NaN | NaN |
| Foreign rate differential-Foreign Tax Jurisdiction Other | NaN | 1,675* | NaN | NaN |
| Effect of cross-border taxes | NaN | 750* | NaN | NaN |
| Research and development credits | NaN | 3,400* | NaN | NaN |
| Changes in valuation allowance | NaN | 100* | NaN | NaN |
| Stock and officers compensation | NaN | 4,025* | NaN | NaN |
| Other | NaN | 625* | NaN | NaN |
| Changes in unrecognized tax benefits | NaN | 1,100* | NaN | NaN |
| Other | NaN | -350* | NaN | NaN |
| Income tax expense | 70,000 | 73,400 | 68,500 | 61,300 |
| Net income | 199,500 | 267,300 | 283,800 | 179,800 |
| Basic EPS | 0.52 | 0.692 | 0.73 | 0.46 |
| Diluted EPS | 0.51 | 0.67 | 0.7 | 0.45 |
| Basic Average Shares | 385,100,000 | 386,500,000 | 391,100,000 | 392,100,000 |
| Diluted Average Shares | 393,600,000 | 398,900,000 | 407,400,000 | 408,200,000 |
DEXCOM INC (DXCM)
DEXCOM INC (DXCM)